Who are Etoricoxib + Cyanocobalamin fixed dose's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etoricoxib-cyanocobalamin-fixed-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Etoricoxib + Cyanocobalamin fixed dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etoricoxib + Cyanocobalamin fixed dose (Etoricoxib + Cyanocobalamin fixed dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 selective inhibitor + vitamin B12 supplement. Area: Pain management / Rheumatology.

phase 3 COX-2 selective inhibitor + vitamin B12 supplement COX-2 enzyme; cyanocobalamin (B12 cofactor) Pain management / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Etoricoxib + Cyanocobalamin fixed dose (Etoricoxib + Cyanocobalamin fixed dose) — Laboratorios Silanes S.A. de C.V.. Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while cyanocobalamin (vitamin B12) supports neurological function and red blood cell formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Etoricoxib + Cyanocobalamin fixed dose TARGET	Etoricoxib + Cyanocobalamin fixed dose	Laboratorios Silanes S.A. de C.V.	phase 3	COX-2 selective inhibitor + vitamin B12 supplement	COX-2 enzyme; cyanocobalamin (B12 cofactor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 selective inhibitor + vitamin B12 supplement class)

Laboratorios Silanes S.A. de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etoricoxib + Cyanocobalamin fixed dose — Competitive Intelligence Brief. https://druglandscape.com/ci/etoricoxib-cyanocobalamin-fixed-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab